Asiaticoside alleviates atherosclerosis progression by suppressing RhoF–NF-κB/MAPK signaling and inflammation in macrophages

AT mitigates AS progression and enhances plaque stability in ApoE^-/- mice by suppressing inflammation through RhoF proteasomal degradation and inhibition of NF-κB/MAPK signaling pathways, highlighting its potential as an anti-atherosclerotic therapeutic agent. These effects may offer advantages over current anti-inflammatory agents, such as tumor necrosis factor (TNF) inhibitors, by targeting protein stability to reduce plaque rupture risk. Its promising clinical translation value warrants further exploration.